Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 6, 2010, Pages 1088-1094

  Kimura, S ^a   Oshima, K ^a   Okuda, S ^a   Sato, K ^a   Sato, M ^a   Terasako, K ^a   Nakasone, H ^a   Kako, S ^a   Yamazaki, R ^a   Tanaka, Y ^a   Tanihara, A ^a   Higuchi, T ^a   Nishida, J ^a   Kanda, Y ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

bioavailability; CsA; drug interaction; pharmacokinetics

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; METHOTREXATE; VORICONAZOLE; ANTIFUNGAL AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; ENTEROPATHY; ENZYME INHIBITION; FEMALE; HUMAN; LIVER DISEASE; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; ALLOTRANSPLANTATION; BIOAVAILABILITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DRUG SYNERGISM; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT; VORICONAZOLE;

EID: 77954861045     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.316     Document Type: Article

References (23)

1. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.
2. Kanda Y, Hyo R, Yamashita T, Fujimaki K, Oshima K, Onoda M et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol 2006; 81: 838-844.
3. Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 2008; 83: 226-232.
4. Holt DW, Mueller EA, Kovarik JM, van Bree JB, Kutz K. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2935-2939. (Pubitemid 24329372)
5. Parquet N, Reigneau O, Humbert H, Guignard M, Ribaud P, Socié G et al. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2000; 25: 965-968.
6. McGuire TR, Honaker M, Lynch JC, Tarantolo SR, Bishop MR, Ketcham MA et al. Renal dysfunction associated with cyclosporine (CSA) prophylaxis in HLA matched sibling peripheral blood stem cell transplantation (AlloBSCT): conversion from intravenous CSA to a new oral formulation (Neoral). Blood 1999; 94(Suppl 1): 334A abstr 1492.
7. Okuda S, Terasako K, Oshima K, Sato M, Nakasone H, Kako S et al. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function. Am J Hematol 2009; 84: 167-169.
8. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
9. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008; 83: 472-476.
10. Kanda Y, Mineishi S, Saito T, Seo S, Saito A, Suenaga K et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-444. (Pubitemid 32201353)
11. Wolf BA, Daft MC, Koenig JW, Flye MW, Turk JW, Scott MG. Measurement of cyclosporine concentrations in whole blood: HPLC and radioimmunoassay with a specific monoclonal antibody and 3H- or 125I-labeled ligand compared. Clin Chem 1989; 35: 120-124.
12. Nakamura Y, Takeuchi H, Okuyama K, Akashi T, Jojima Y, Konno O et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. Transplant Proc 2005; 37: 1725-1727.
13. Ku YM, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol 1998; 38: 959-965.
14. Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant 2004; 33: 137-152.
15. Dresser GK, Spence JD, Bailey DG. Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
16. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014-1018.
17. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dosedependent effect? Ann Pharmacother 1993; 27: 427-430.
18. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous highdose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268-1272.
19. Mihara A, Mori T, Aisa Y, Yamazaki R, Iketani O, Tanigawara Y et al. Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. Eur J Clin Pharmacol 2008; 64: 89-91.
20. Kramer MR, Merin G, Rudis E, Bar I, Nesher T, Bublil M et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Transplant Proc 1997; 29: 2657-2659.
21. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau DP. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003; 35: 2873-2877.
22. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12: 325-334.
23. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009; 44: 371-374.